SLC5A2 and diabetes mellitus: However, since dapagliflozin is still authorized for type 2 diabetes mellitus and the risk of ketoacidosis was observed with all SGLT2 inhibitors, patients treated with these drugs should be carefully monitored, also to reduce the dangerous complications of ketoacidosis.